Trials / Completed
CompletedNCT06973681
A Study of BGM0504 Evaluating Weight Loss in Overweight or Obese Chinese Subjects
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase II Clinical Study to Evaluate the Safety, Tolerability, PK/PD Profile, and Efficacy of Multiple Doses of BGM0504 Injection in Overweight or Obese Subjects Without Diabetes
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
To assess the effect of BGM0504 injection versus placebo on weight loss in overweight or obese subjects after 24 weeks of treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BGM0504 | Administered SC |
| DRUG | BGM0504 | Administered SC |
| DRUG | BGM0504 | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2023-10-13
- Primary completion
- 2024-09-13
- Completion
- 2024-09-13
- First posted
- 2025-05-15
- Last updated
- 2025-05-15
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06973681. Inclusion in this directory is not an endorsement.